Clinical trial · Observational
Global Cardio Oncology Registry
NCT05598879CI-TRIAL-00111155G-CORrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cardiotoxicity | — | UNRESOLVED | — |
| Cardiovascular Diseases | — | UNRESOLVED | — |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Immune Checkpoint Inhibitor-Related Myocarditis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anonymized data collection during programmed surveillance clinical follow up | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Breast cancer
- description
- Patients with breast cancer who present for initial cardio-oncology consultation. Clinical follow up for 18 months.
- interventionNames
- Other: anonymized data collection during programmed surveillance clinical follow up
- label
- Hematological malignancies
- description
- Patients with lymphomas, leukemias, multiple myeloma, and AL amyloidosis who present for initial cardio-oncology consultation. Clinical follow up for 18 months.
- interventionNames
- Other: anonymized data collection during programmed surveillance clinical follow up
- label
- Immune check point inhibitors
- description
- Patients with any type of cancer treated with immune check point inhibitors who present for initial cardio-oncology consultation. Clinical follow for 18 months
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * New cardio-oncology consultation for breast cancer patients, or * New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or * New cardio-oncology consultation for acute or chronic leukemia patients, or * New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or * New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation. * All patients have to be 18 years old or older Exclusion Criteria: * Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators. * Minors less than 18 years old. * Inability or unwillingness to consent to participate
References
Publications (0)
Data not yet available
No reference posted for this study.